Poseida Therapeutics Inc (PSTX)

[jondoeuk]

Link to webcast https://wsw.com/webcast/cc/pstx5/1465560

Slides https://investors.poseida.com/static-files/00aa2f74-8058-4a80-982f-b441664c9db1

[jondoeuk]

R&D Day PR https://www.prnewswire.com/news-releases/poseida-therapeutics-hosts-third-annual-virtual-rd-day-highlighting-novel-pipeline-assets-and-latest-technology-innovations-301752568.html

[beambe]

good NEWS

[beambe]

https://poseida.com/science/pipeline/

[beambe]

Volume: 544,284

[beambe]

Volume

[beambe]

good News

[trendzone]

The usual greedy bigs.

[retireat40]

Dropped an offering at 4:01pm. Greedy schmucks.

[beambe]

https://www.nasdaq.com/market-activity/stocks/pstx/institutional-holdings

[jondoeuk]

Link to webcast https://event.on24.com/wcc/r/3876127/0CBE308BDD621EB200051542826DCC8C

Slides https://investors.poseida.com/static-files/472c5468-0ae7-4bdb-9cf9-f6050ddf58eb

[jondoeuk]

They have announced a partnership with RHHBY to jointly develop allo CAR-T therapies. Per the terms, the Swiss pharma giant will receive either exclusive rights or options from Poseida to develop and sell multiple CARs globally against targets in multiple myeloma, B-cell lymphomas, and other hematologic malignancies. In return, Poseida will receive $110M of upfront payment in addition to $110M in near-term milestones and other payments within the next several years. Notably, the company is entitled to receive up to $6B worth of milestones and other payments based on research, development, launch, and net sales. The completion of the agreement is subject to clearance under the HSR Act.

[KOmani]

This would be so easy without the $6 billion tossed in casually at the end.

[KOmani]

Damn.

It also said it is eligible to receive up to $6 billion in research, development, launch and other payments, along with royalties on product sales.

[subslover]

Poseida Therapeutics Inks Collaboration With Roche
August 03 2022 - 08:18AM
Dow Jones News
Alert
Print
Share On Facebook
By Colin Kellaher


Poseida Therapeutics Inc. on Wednesday said it signed a collaboration and license agreement potentially worth billions of dollars with Swiss pharmaceutical company Roche Holding AG.

San Diego-based Poseida, a clinical-stage biopharmaceutical company, said the deal covers the research and development of multiple existing and novel "off-the-shelf" cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications.

Poseida said it would receive an upfront payment of $110 million, and that it could receive up to $110 million in near-term milestones and other payments over the next several years.

It also said it is eligible to receive up to $6 billion in research, development, launch and other payments, along with royalties on product sales.

Trading in shares of Poseida, which closed Tuesday at $2.43, was halted premarket on Wednesday.

[jondoeuk]

https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-interim-results-from-phase-1-trial-of-p-psma-101-at-asco-genitourinary-cancers-symposium-301484390.html

Video https://poseida.com/wp-content/uploads/2022/02/Audio-P-PSMA-101-ASCO2022.mp4

Slides https://poseida.com/wp-content/uploads/2022/02/P-PSMA-101-ASCO-GU2022-Speaker-Slides-27Jan22-FINAL.pdf

Poster https://poseida.com/wp-content/uploads/2022/02/P-PSMA-101-ASCO-GU2022-Poster-27Jan22-FINAL.pdf

[jondoeuk]

R&D Day
Wed, Feb 23 (10:00am - 1:30pm ET / 7:00am - 10:30am PT)
https://wsw.com/webcast/cc/pstx4/1464498

[jondoeuk]

SITC posters

Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control https://poseida.com/wp-content/uploads/2021/11/16344-YanZhang-Poster.pdf

P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor https://poseida.com/wp-content/uploads/2021/11/Final-SITC-Poster-BCMA-ALLO-Memory.pdf

[jondoeuk]

ASH PR https://www.prnewswire.com/news-releases/poseida-therapeutics-provides-update-on-bcma-targeted-car-t-clinical-trials-at-the-2021-american-society-of-hematology-ash-annual-meeting-301442793.html

[jondoeuk]

The company has entered into a research collaboration and exclusive license agreement with Takeda Pharma. Under the terms of the agreement, the parties will collaborate to initially develop up to six in vivo gene therapy programs utilising Poseida's tech platforms, including piggyBac, Cas-CLOVER and biodegradable nanoparticles, as well as certain emerging technologies. Takeda also has an option to add two additional programs and is obligated to provide funding for all R&D costs. Poseida will receive an upfront payment of $45M and preclinical milestones, potentially exceeding $125M. They are also eligible to receive future milestone payments of up to $2.7B for all six programs, and up to $3.6B related to additional two optional programs.

[jondoeuk]

SITC:

Title: Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1) Correlates with In Vivo Tumor Control
Presenter: Hubert Tseng, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 147

Title: P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy with Broad Potential in Solid Tumor
Presenter: Yan Zhang, Ph.D., Poseida Therapeutics
Session Date/Time: ePoster Hall opens November 12, 2021, at 7:00am ET
Abstract Number: 123

[jondoeuk]

Slide decks from the CAR-TCR Summit

Developing CAR-T Cells for Multiple Myeloma: From Autologous to Allogeneic https://poseida.com/wp-content/uploads/2021/08/Matt-Spear_BCMA-CAR-TCR21-final-210831.pdf

Advancing Nonviral Manufacturing for Multi-Product Allogeneic T-Cell Therapies https://poseida.com/wp-content/uploads/2021/09/210901-Shedlock-CAR-TCR-Summit-2.pdf

Developing piggyBac Systems “Off-the-Shelf” CAR-T Cells for Bone Marrow Transplant Conditioning https://poseida.com/wp-content/uploads/2021/08/Nina-Timberlake_20210902-CAR-TCR-Beyond-Oncology.pdf

[jondoeuk]

As of the cutoff date, the trial had enrolled a total of nine patients with mCRPC. Five were treated with Dose A (an average of about 20M cells), and four with Dose B (an average of about 60M cells). Patients were heavily pre-treated, having received an average of six prior lines of therapy. Five showed measurable declines in PSA levels, with three showed a greater than 50% decline. One demonstrated evidence of complete tumour elimination and remains in a durable response of greater than five months at the time of this presentation https://poseida.com/wp-content/uploads/2021/08/CAR-TCR-Summit-2021_P-PSMA-101-Update_08312021.pdf

[jondoeuk]

The company plans to provide an update from the PhI P-PSMA-101 trial to be presented by CEO, Eric Ostertag, at the 6th Annual CAR-TCR Summit virtual meeting at 10:00 am ET on August 31, entitled, "P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer.''

[jondoeuk]

Presentations at the American Society of Gene and Cell Therapy Annual Meeting;

Preclinical Evaluation of Combined Adeno-Associated Virus and Nanoparticle Delivery of piggyBac Transposon System for Durable Transgene Expression in the Growing Neonatal Murine Liver https://poseida.com/wp-content/uploads/2021/05/ASGCT-2021-In-vivo-gene-therapy-JJ_FINAL.pdf

In a preclinical study, Poseida evaluated concomitant delivery of recombinant adeno-associated virus (rAAV) vectors and novel nanoparticle (NP) vectors using its piggyBac and "Super" piggyBac (SPB) technologies in order to deliver transposon and transposase in a growing neonatal mouse model. Data demonstrated that the piggyBac DNA Delivery System was effective in using both rAAV and NP vectors to introduce edited genes into targeted hepatocyte genomes. Poseida also found that SPB, a hyperactive form of the transposase, produced stable vector integration into the hepatocyte genome for more than three months, compared to transpose alone. Similarly, delivery of a novel NP formulation using SPB produced efficient delivery of mRNA to the liver hepatocytes, with similarly high levels of durability in the transgene expression. Taken together, these preclinical findings suggest the potential of piggyBac and SPB technology for gene therapies that treat congenital liver disease in infants and young children.

P-BCMA-ALL01: A Fully Allogeneic Stem Cell Memory T Cell (TSCM) CAR-T Therapy Targeting BCMA for the Treatment of Multiple Myeloma Shows Potent Anti-Tumor Activity https://poseida.com/wp-content/uploads/2021/05/ASGCT-2021-P-BCMA-ALLO1-Poster-Max-Richter.pdf

P-BCMA-ALLO1 is Poseida's first fully allogenic product candidate targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma. In in vitro and in vivo preclinical studies, P-BCMA-ALL01 showed effective, targeted cancer cell killing and cytokine secretion, with similar or superior performance in anti-tumor efficacy compared to an autologous CAR-T therapy. Inclusion of a proprietary "booster molecule" in the allogeneic manufacturing process further improved expansion of gene-edited cells and enabled production of hundreds of patient doses from a single manufacturing run, thereby reducing the manufacturing cost per dose into the same range as that of a monoclonal antibody.

Anti-c-kit CAR-T Cells Afford Effective Eradication of Human AML and Normal Hematopoietic Cells in a Preclinical Model of Safer Non-Genotoxic Stem Cell Transplant Conditioning https://poseida.com/wp-content/uploads/2021/05/ASGCT-2021-Poster-Deck-cKit-Nina-Timberlake.pdf

Poseida is investigating its anti-c-kit CAR-T program, which leverages its proprietary piggyBac DNA Delivery System in preclinical studies as a potentially safer precursor conditioning therapy to the transplantation of hematopoietic stem cells (HSC) for patients suffering from AML. The piggyBac delivery vectors under investigation include a transposon that generates pure CAR+ product as well as a safety switch that allows rapid clearance of the reactive CAR-T cells prior to donor transplant of hematopoietic stem cells. Preclinical data to be presented in the poster showed that the lead CAR-T cells that express the anti-c-kit binder (CAR 1) deplete up to 92% of human CD34+ stem and progenitor cells in bone marrow within 48 hours. Additionally, an enhanced anti-c-kit CAR-T product, CAR 2, killed an estimated >99% of leukemia cells, exceeding the killing ability of a single dose of 30 mg/kg dose of busulfan. These encouraging data suggest that stem cell-directed CAR-T cells may be a safer preconditioning regimen compared to the current standard of care and may expand access to treatment for acute myeloid leukemia patients needing HSC transplant.

[jondoeuk]

Slides https://investors.poseida.com/static-files/49ba1622-3013-4ac5-90dd-58119c2ed2cd

[jondoeuk]

R&D Day https://wsw.com/webcast/cc/pstx/1409274

[jondoeuk]

ASH slides https://poseida.gcs-web.com/static-files/cfd40f97-eac8-4226-8a2c-f4ea58207ab9

[jondoeuk]

ASH abstract https://ash.confex.com/ash/2020/webprogram/Paper142695.html

[jondoeuk]

Data from TScan https://www.cell.com/immunity/fulltext/S1074-7613(20)30447-7

[jondoeuk]

The company and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.

The allo T-cell platform will be used in combination with TScan's immunodominant epitopes and TCR sequences for the development and commercialisation of TCR-T cell therapies.

[jondoeuk]

SITC

Just one entitled: P-MUC1C-ALLO1: An Allogeneic CAR-T for Multiple Solid Tumor Indications

[jondoeuk]

Yes, I am. My position was reduced after the FDA hold on PSMA-101, but I will wait for the updated data at ASH from BCMA-101. This could inform the potentially registrational PhII trial (including a possible outpatient cohort). Also, work on a number of improvements is ongoing (see my second post).

[Mr Krabs]

Hey are you still there I would like to know what you think about this company now

[jondoeuk]

Slides https://investors.poseida.com/static-files/7bb33fc4-5c79-4c96-a849-8df23f70f4ce

[jondoeuk]

The company will provide an initial presentation of certain manufacturing improvements and related clinical data for the expanded PhI P-BCMA-101 trial with a late breaking abstract by the CEO to be presented at the CAR-TCR Digital Week virtual meeting on Sept 16.